Hims & Hers Health, Inc. Shareholders Who Lost Money on Their Investment are Encouraged to Contact Johnson Fistel about the Class Action Investigation
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) regarding possible violations of federal securities laws. Investors who purchased Hims & Hers securities may be eligible to recover losses stemming from alleged misrepresentations and omissions made by the company and its executives.
What if I purchased Hims & Hers securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your losses, follow the link provided:
https://www.johnsonfistel.com/investigations/hims-hers-health-inc
For more information, contact James Baker at (619) 814-4471, [email protected] or [email protected].
On June 23, 2025, Novo Nordisk terminated its collaboration with Hims & Hers Health, citing serious concerns over the company's sale of compounded medications marketed as personalized treatments. According to Novo Nordisk, Hims allegedly skirted regulations by mass-distributing semaglutide-based drugs that may contain unauthorized foreign substances, raising significant safety red flags. This development has prompted increased scrutiny of Hims' business practices and legal compliance.
About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.
Achievements:
In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries.
Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Takeda Announces New Assignments of Directors
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company's values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success. Details of the new assignments are as follows: 1. New Assignment of Directors Who Are Not Audit and Supervisory Committee Members (Effective June 25, 2025) 2. Directors Who Are Audit and Supervisory Committee Members 3. New Assignment of Nomination Committee and Compensation Committee Members (Effective June 25, 2025) Nomination committee: Masami Iijima (Chairperson), Steven Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel and Yoshiaki Fujimori (Observer: Christophe Weber) Compensation committee: Emiko Higashi (Chairperson), John Maraganore, Michel Orsinger, Miki Tsusaka and Kimberly A. Reed About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Important Notice For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.
Business Insider
2 hours ago
- Business Insider
Canaccord Genuity Sticks to Their Buy Rating for Bank Of Montreal (BMO)
Canaccord Genuity analyst Matthew Lee maintained a Buy rating on Bank Of Montreal (BMO – Research Report) today and set a price target of C$166.00. The company's shares closed today at $106.73. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Lee covers the Industrials sector, focusing on stocks such as CAE, Air Canada, and Diversified Royalty Corp. According to TipRanks, Lee has an average return of 13.1% and a 65.05% success rate on recommended stocks. In addition to Canaccord Genuity, Bank Of Montreal also received a Buy from RBC Capital's Darko Mihelic in a report issued on June 9. However, on the same day, Barclays downgraded Bank Of Montreal (NYSE: BMO) to a Hold. BMO market cap is currently $76.08B and has a P/E ratio of 13.59.
Yahoo
4 hours ago
- Yahoo
Earnings To Watch: Lindsay (LNN) Reports Q2 Results Tomorrow
Agricultural and farm machinery company Lindsay (NYSE:LNN) will be announcing earnings results this Thursday morning. Here's what investors should know. Lindsay beat analysts' revenue expectations by 4% last quarter, reporting revenues of $187.1 million, up 23.5% year on year. It was an incredible quarter for the company, with a solid beat of analysts' organic revenue estimates and an impressive beat of analysts' EPS estimates. Is Lindsay a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lindsay's revenue to grow 16.4% year on year to $162 million, a reversal from the 15.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.41 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lindsay has missed Wall Street's revenue estimates four times over the last two years. With Lindsay being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for heavy machinery stocks. However, there has been positive investor sentiment in the segment, with share prices up 2.9% on average over the last month. Lindsay is down 1.1% during the same time and is heading into earnings with an average analyst price target of $139 (compared to the current share price of $138.22). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
